MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2022 International Congress

    Blood-derived α-synuclein from Parkinson´s disease patients is able to seed pathology

    A. Kluge, J. Bunk, E. Schäffer, H. Knacke, A. Drobny, W. Xiang, R. Lucius, P. Arnold, F. Zunke, D. Berg (Kiel, Germany)

    Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients. Background: PD pathology is…
  • 2022 International Congress

    Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons

    G. Virdi, M. Choi, J. Evans, S. Strohbuecker, M. Horrocks, R. Patani, S. Gandhi (London, United Kingdom)

    Objective: Develop and adapt a differentiation paradigm to produce enriched hiPSC-derived midbrain dopaminergic neurons (mDA), to resolve the temporal sequence of pathophysiological events in synucleinopathies.…
  • 2022 International Congress

    CSF biomarkers in neurodegenerative parkinsonism can distinguish between multiple system atrophy and 4-repeat tauopathies, but not between disease with Lewy bodies and multiple system atrophy

    P. Kanovsky, K. Bucilova, M. Chudackova, D. Konickova, K. Pekarova, K. Sklenarova, M. Kaiserova, S. Kurcova, M. Nevrly, J. Zapletalova, M. Strnad, K. Mensikova (Olomouc, Czech Republic)

    Objective: To assess the usefulness of a defined set of blood-based and cerebrospinal fluid-based biomarkers in the differential diagnosis of neurodegenerative proteinopathies. Background: The diagnostic…
  • 2022 International Congress

    GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease

    B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj (Lugano, Switzerland)

    Objective: Demonstrate the involvement of our structurally targeted allosteric regulator Parkinson’s disease (PD) candidate, GT-02287, in decreasing the CBE-induced neurotoxic effect and in restoring lysosomal…
  • 2022 International Congress

    Design of a prodromal screening study for subtypes in Parkinson’s Disease

    E. Schaeffer (Kiel, Germany)

    Objective: To follow-up prodromal Parkinson’s Disease (PD) subtypes in a longitudinal cohort study, validating new biomarkers and ethical guidelines for early detection of PD. Background:…
  • 2022 International Congress

    Multidimensional phenotyping of human stem cell-derived midbrain dopaminergic neurons from a SNCA triplication carrier for drug screening applications

    J. Wilbertz, V. Gorgogietas, L. Cousin, A. Vuidel, I. Boussaad, R. Krüger, P. Sommer (Strasbourg, France)

    Objective: We hypothesized that combining multiple Parkinson's disease (PD) relevant cellular phenotypes will increase the accuracy, stability, and usability of human midbrain dopaminergic (mDA) neuronal…
  • 2022 International Congress

    Genetic stratification of motor and quality of life outcomes in Parkinson’s disease in the EARLYSTIM study

    D. Weiss, Z. Landoulsi, P. May, M. Sharma, M. Schüpbach, H. You, JC. Corvol, S. Paschen, AK. Helmers, M. Barbe, G. Fink, A. Kühn, C. Brefel-Courbon, L. Wojtecki, P. Damier, V. Fraix, JL. Houeto, J. Regis, F. Sixel-Döring, M. Pinsker, S. Thobois, A. Gharabaghi, V. Stoker, L. Timmermann, A. Schnitzler, P. Krack, M. Vidailhet, G. Deuschl, R. Krüger (Tübingen, Germany)

    Objective: We identified (Weiss et al., 2016) that single nucleotide polymorphism (SNPs) of the alpha-synuclein gene (SNCA) predicted the motor effect of subthalamic nucleus stimulation (STN-DBS)…
  • 2022 International Congress

    Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months

    C. Wakade, M. Seamon, S. Purohit, J. Morgan, R. Chong (Augusta, USA)

    Objective: The main objective was to determine if α-synuclein could be modulated by niacin supplementation, contributing to improved Parkinson’s disease (PD) symptoms. Background: Niacin supplementation…
  • 2022 International Congress

    The role of GBA1 mutations in the relationship between GBA1 and alpha-synuclein in Parkinson disease

    L. Smith, M. Gegg, D. Chau, AHV. Schapira (London, United Kingdom)

    Objective: The aim of the study was to understand how the E326K GBA1 mutation results in an increased risk for Parkinson disease, through influencing the…
  • 2022 International Congress

    Lack of Toll-like receptor 4 is associated with accumulation of alpha-synuclein in the midbrain Parkinson’s disease mice.

    C. Conte, G. Mariucci, R. Cafaro (Perugia, Italy)

    Objective: In this study we aimed to investigate the potential role of Toll-like receptor 4 (TLR4) in mediating both the dopaminergic neuron loss and alpha-synuclein (alpha-SYN)…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley